Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

What Is the Analyst Consensus on Nanosonics (ASX:NAN)?

Nanosonics (ASX:NAN) carries a consensus analyst rating of Buy. Of the 7 analyst recommendations recorded, 5 are Buy or equivalent, 2 are Hold and 0 are Sell or equivalent. The mean price target is A$3.88, with targets ranging from A$3.20 to A$5.15, against a …

Sonal Goyal | 09 October 2026

EMVision Medical Devices (ASX:EMV) Advances Brain Scanner Trial as Patient Recruitment Grows

On 31 August 2026, EMVision (ASX:EMV) reported more than 200 patients enrolled across the trial’sTrainingand primary-analysis cohorts. The company also stated that no device-related adverse events had been reported at that point. That observation does not establish diagnostic accuracy or guarantee regulatory approval. Recruitment …

Aditi Sarkar | 09 October 2026

Cochlear Limited (ASX:COH): FY26 Profit Reset, Nexa Adoption and FY27 Outlook

Cochlear Limited (ASX:COH) is the global leader in implantable hearing solutions, according to its official website, with products spanning cochlear and bone-conduction implant systems. The company’s FY26 result shows a year of softer implant revenue and lower margins alongside product adoption, improved cash generation …

Aditi Sarkar | 08 October 2026

CSL Limited (ASX:CSL): What FY26 Reset Means for Earnings and FY27 Priorities

CSL Limited (ASX:CSL) is a global biopharma company focused on plasma-derived therapies, vaccines and medicines for serious and complex diseases. Its FY26 result shows a business undergoing a broad reset: underlyingEarningsremained profitable, but restructuring and impairment charges moved the statutory result into loss. The …

Aditi Sarkar | 08 October 2026

Is Neogen (NASDAQ:NEOG) Finally Turning the Corner After an October 6 Beat and a Guidance Raise to USD 885 Million to USD 890 Million, and What Could Happen Next for Neogen (NASDAQ:NEOG)?

Neogen (NASDAQ:NEOG) reported fiscal first-quarter 2027revenueofUSD 222.8 millionon October 6, 2026, up 6.5 percent and 8.1 percent on a core basis, above itsoutlookrange ofUSD 207 milliontoUSD 209 million.

Vinay Lochav | 08 October 2026

Why Did Medtronic (NYSE:MDT) Cap Its MiniMed Offer at 4.5939, and What Could Happen Next for Medtronic (NYSE:MDT)?

In a release at 5:31 p.m. ET on October 7, 2026, Medtronic (NYSE:MDT) said the final exchange ratio is 4.5939 MiniMed shares for each Medtronic ordinary share accepted. The company indicated that that the calculated ratio would have exceeded the upper limit of 4.5939, …

Vinay Lochav | 08 October 2026

Ansell Limited (ASX:ANN): FY26 Earnings Growth and FY27 Guidance Shape the Next Phase

Ansell Limited is a global provider of personal protection and safety solutions, serving customers across healthcare and industrial markets. In FY26, the company reported higher sales,Earningsand cash flow while navigatingTariffand supply-chain pressures. The result also sets the context for FY27, when management is focusing …

Aditi Sarkar | 08 October 2026

Why Did argenx (NASDAQ:ARGX) Sink 16% Premarket on a Trial Stop, and What Could Happen Next for argenx (NASDAQ:ARGX)?

In a release issued at 7:00 a.m. CET on October 8, 2026 (1:00 a.m. ET), argenx said it will discontinue the Phase 3 UNITY study of efgartigimod SC in adults with moderate to severe Sjögren's disease. An independent data monitoring committee recommended stopping after …

Vinay Lochav | 08 October 2026

What Ramsay Health Care (ASX:RHC) Investors Should Weigh as the Ramsay Santé Demerger Vote Nears in the ASX 200

Ramsay reported FY26 underlying EBIT of A$1.1622 billion, up 11.5% from A$1.0426 billion in FY25. Underlying NPAT attributable to shareholders increased 19.3% to A$364.1 million.

Sonal Goyal | 08 October 2026

What Sonic Healthcare (ASX:SHL) Gained and Gave Up in a Year of Acquisition-Led Growth in the ASX 200

Sonic reported FY26Revenueof A$10.867 billion, up 12.7% from the prior year.

Sonal Goyal | 08 October 2026
Support

Hi! How can we help you today?

Loading…